What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
CNTF-derived neurogenic peptide (DGGL core) with adamantane moiety
Overview
P21 (also designated P021) is a synthetic peptide derived from the biologically active region of human ciliary neurotrophic factor (CNTF), corresponding to amino acid residues 148-151. It was developed at the New York State Institute for Basic Research in Khalid Iqbal's laboratory as an effort to distill CNTF/Cerebrolysin-like neurotrophic activity into a single, well-defined small molecule. Its C-terminus is modified with an adamantylated glycine to increase lipophilicity and, in theory, blood-brain barrier penetration, along with metabolic stability against exopeptidase degradation. The compound is currently in preclinical drug development by Phanes Biotech (Malvern, Pennsylvania, USA) and has been extensively studied across multiple rodent models — 3xTg-AD Alzheimer's disease mice, aged rats, Down syndrome (Ts65Dn) mice, and CDKL5 knockout epileptic encephalopathy mice — but no human clinical trial data exist. It is intended for RUO (research-use-only) purposes only. Vialdyne releases P21 (P021) as a lyophilized modified pentapeptide (n-acetylated, c-amidated dggl tetrapeptide core capped with one non-standard adamantyl-glycine residue) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For in vivo workflows, endotoxin and microbial-limit testing on the specific lot is recommended at the COA stage.
Primary buyer fit: academic and contract research laboratories.
Specifications
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
P21 is supplied as a lyophilized solid, which is its most stable form for shipping and long-term holding. Keep sealed vials frozen and desiccated, and bring them to room temperature before opening to limit moisture condensation onto the cake. The adamantyl-glycine cap raises hydrophobicity, so reconstitution may benefit from a small fraction of an appropriate co-solvent before dilution into the working buffer rather than forcing the peptide into pure aqueous medium. Aliquot the reconstituted stock to avoid repeated freeze-thaw, record the preparation date, and hold working solutions cold and briefly to preserve activity through an experiment.
Because P21 pairs a short active core with a non-natural adamantyl-glycine modification, the certificate should confirm the intended modified mass by mass spectrometry, not merely the unmodified core, and demonstrate purity by RP-HPLC with related impurities quantified. Ask for net-peptide content so the modification and any counter-ion and moisture are accounted for in what you weigh out. For a compound whose value depends on the delivery modification being present and intact, the analytical package should make clear that the cap is incorporated as designed rather than partially cleaved, since a stripped core would behave very differently in CNS-exposure work.
Related peptides
